Company Location Date Amount (M) Investors/ Details
JANUARY
Adolor Corp. Malvern, Pa. 1/19 $12.30 Adolor raised $12.3M in a private placement that drew previous investors Alta Partners, ARCH Venture Partners, Falcon Technology Partners, OneLiberty Partners, S.R. One Ltd., TL Ventures, Tredegar Investments, and Weiss, Peck & Greer Venture Partners; OrbiMed Advisors participated in this 5th round of financing as well
Conjuchem Inc. Montreal 1/12 C$3.9 (US$2.7) Conjuchem raised C$3.9M (US$2.7M) in a private placement with the China Development Industrial Bank (C$3.5M) and MVI Medical Venture Investments Ltd. (C$0.4M), a subsidiary of New Medical Technologies
Esperion Therapeutics Inc. Ann Arbor, Mich. 1/13 $22 Esperion raised $22M in Series C financing that included existing investors TL Ventures, Oak Investment Partners, and HealthCap KB; new investors included Canaan Partners and Avalon Investments; the financing was co-led by TL Ventures and Canaan Partners
Iceland Genomics Corp. Reykjavik, Iceland N/A $8 Iceland Genomics raised $8M in 2nd financing round; Burdaras Ltd., of Reykjavik, was lead investor; four other Icelandic investors also participated: Nyskopunarsjodur (New Business Venture Fund), Throunarfelag, Uppspretta and Nesey Holdings AS
Icon Genetics AG Munich, Germany 1/20 $12 Icon s 1st round raised $12M through a combination of venture capital financing, long-term debt, research grants and contracts
Illumina Inc. San Diego 1/10 $28 Illumina raised $28M in a private equity financing that drew new investors Tisch Family Fund, Lombard Odier & Cie, State Farm Automobile Insurance Co., Chase Capital Partners, PE Corp., the Dow Chemical Co., and Chevron Technology Ventures; all existing investors Venrock Associates, ARCH Venture Partners, CW Group and Tredegar Investments participated
Insmed Pharmaceuticals Inc. Richmond, Va. 1/27 $34.50 Insmed raised $34.5M through the sale of 5.6M shares of common stock to a group of investors led by Cooper Hill Partners LLC; other members included funds managed by OrbiMed Advisors, Quantum Partners and Vector Fund Management; investors also received warrants, exercisable for 5 years, to buy the equivalent of 2M additional shares
Intellivax International Inc. Saint Laurent, Quebec C$12.5 (US$8.6) Intellivax raised C$12.5M (US$8.6M) from Montrealbased investors The Business Bank of Canada, the Solidarity Fund, BioCapital, La Societe Innovatech du Grand Montreal, and Royal Bank Ventures Inc.
InterMune Pharmaceuticals Inc. Palo Alto, Calif. 1/10 $27 InterMune raised $27M in oversubscribed private placement of Series B preferred stock; new investors were Alta Partners and E.M. Warburg, Pincus & Co. LLC, which led the financing; all existing investors in the company participated in the deal, including Genentech Inc., Sanderling, BioAsia Investments LLC, Sofinnova Ventures, Charter Ventures and Connetics Corp.
Keryx Biopharmaceuticals Inc. Jerusalem (incorporated in Delaware) 1/25 $8.80 Keryx raised $8.8M in a private placement of convertible preferred stock; leading the placement were Paramount Capital Inc. and Leumi & Co. Underwriters
NetGenics Inc. Cleveland 1/12 $21.30 NetGenics raised $21.3M in an equity financing; Muzinich & Company, also an investor, served as placement agent for the financing, led by Dresdner Kleinwort Benson and including Lombard Odier & Cie and KECALP Inc. (an affiliate of Merrill Lynch & Co.); previous investors who participated include OrbiMed Advisors LLC, WPG-Farber Present Fund LP and Crystal Internet Venture Fund
Neurochem Inc. St. Laurent, Quebec 1/26 C$7.9 (US$5.5) Neurochem received a commitment from Technology Partnerships Canada to invest C$7.9M (US$5.5M) in research and development of a lead compound for Alzheimer s disease; the TPC investment covers a period of 3 years and will be reimbursed from royalties on sales
Neuron Therapeutics Inc. Malvern, Pa. 1/12 $12.20 Neuron raised $12.2M through a private placement to a syndicate of 7 venture capital firms, including Chase Capital Partners, Crescendo Ventures, New Enterprise Associates, Spray Venture Fund, Bank of America Ventures, U.S. Bancorp Piper Jaffray Ventures and The Vertical Group
Orchid Biocomputer Inc. Princeton, N.J. 1/6 $72 Orchid self-managed 2nd round of venture capital equity financing, raising $72M; new investors include Affymetrix Inc., Oracle Strategic Partners LP, AP Asset Management Fund, International BioMedicine Partners, Burrill AgBioCapital Fund LP and the Taiwan Investment Group; existing investors who participated include Oxford Bioscience Partners, INVESCO Funds Group, WPG Farber, Present Fund LLC, and OrbiMed Advisors LLC; Affymetrix served as lead corporate investor
TransTech Pharma Inc. High Point, N.C. 1/18 $4 TransTech received an equity investment of $4M from MacAndrews & Forbes Holdings Inc.
TranXenoGen Inc. Shrewsbury, Mass. 1/12 $1.60 TranXenoGen raised $1.6M through a placement of Series B preferred stock to a group of private investors; financing primarily involved Kim Tan, CEO of KS Biomedix Holdings plc, in London, and other UK and U.S. investors
Viron Therapeutics Inc. London, Ontario 1/14 C$7.3 (US$5M) Viron raised C$7.3M (US$5M) in a placement of Series A and B preferred shares; the financing was led by The Novartis Venture Fund, and included Royal Bank Ventures Inc. (part of the Royal Bank Financial Group of Companies), GeneChem Technologies Venture Fund L.P., the Eastern Technology Seed Investment Fund, Trudell Medical Ltd., the New Medical Technologies Fund, and private investors; Viron is extending the finance closing on similar terms for a further 3 months to allow additional investors to complete their investments
Xanthon Inc. Research Triangle Park, N.C. 1/5 $4 Xanthon entered a $4M asset financing agreement with Oxford Venture Finance to fund the purchase of laboratory and manufacturing equipment
FEBUARY
Cythera Inc. San Diego 2/3 $2 Cythera raised $2M in initial round of venture financing from Sanderling, Alta Partners and Graystone Venture Direct Equity
Deltagen Inc. Menlo Park, Calif. 2/1 $22.50 Deltagen raised $22.5M in round led by Boston Millennia Partners and including investments from The Sprout Group, Baccharis Capital, Crossroads and Lombard Odier & Cie
Digital Gene Technologies Inc. La Jolla, Calif. 2/10 $22 Digital Gene raised $22M in an oversubscribed, self-managed equity placement that attracted both new and previous investors
DoubleTwist Inc. (formerly Pangea Systems Inc.) Oakland, Calif. 2/23 $37 DoubleTwist raised $37M in a Series D equity financing; MPM Asset Management led the financing, which also included new investors T. Rowe Price, INVESCO Global Health Sciences Fund, Lone Pine Capital LLC and Amerindo Investment Advisors; previous investors who participated included Institutional Venture Partners, Mayfield Fund, Kleiner Perkins Caulfield & Byers, MDS Capital, Boston Millennia Partners, Burrill & Company, Moss Forest Ventures, and Levensohn Capital Management
GeneFormatics Inc. San Diego 2/12 $4 GeneFormatics raised $4M in financing led by Burrill & Company s AgBio Capital Fund; IngleWood Ventures co-invested and participants included Moss Forest Ventures
Genometrix Inc. The Woodlands, Texas 2/8 ND Genometrix completed a private placement that attracted previous investors Motorola Inc., New Renaissance Ventures, and Fayes Sarofim & Co.
Merix Bioscience Inc. Research Triangle Park, N.C. 1/31 $1.90 Senmed Medical Ventures and other coinvestors invested $1.9M, with an option to invest an additional $5M to $10M in in the next round based on the accomplishment of various milestones
Octagen Corp. Bala Cynwid, Pa. N/A $4.50 Octagen closed a 2nd-round $4.5M financing; Bal Cap Biotech LP, an affiliate of Balanced Capital, was the lead investor
Phytera Inc. Worcester, Mass. 2/3 $9.10 Phytera raised $9.1M in a private equity financing that attracted new and existing investors in Europe, Asia and the U.S.; Index Securities, of Geneva, and SG Cowen Securities Corp. acted as placement agents
Spherics Inc. Providence, R.I. 2/17 $4 Spherics raised $4M in 1st-round financing; Zero Stage Capital, of Cambridge, led the financing, with a $3.25M investment; CB Health Ventures, of Boston, also participated
VistaGen Inc. Mountain View, Calif. 2/16 $1 VistaGen raised $1M in a private placement
MARCH
Achillion Pharmaceuticals Inc. New Haven, Conn. 3/27 $17 Achillion raised $17M in first round of financing, attracting investments from Schroder Ventures, Atlas Venture, Advent International, and Connecticut Innovations Inc.
AlphaVax Inc. Durham, N.C. 3/7 $8.20 AlphaVax raised $8.2M in Series B financing, which attracted domestic and overseas institutions, as well as venture capital funds and individuals; Burton Advisors Ltd. (London) acted as placement agent
Axxima Pharmaceuticals AG (formerly VirGene Pharmaceuticals AG) Martinsried, Germany 3/10 DM20 (US$9.88) Axxima raised $9.88M in oversubscribed second-round financing; TVM Techno Ven ture Management GmbH was lead investor and coordinated the round; the other participants were International Biotechnology Trust plc (UK); Alpinvest (Netherlands); Global Life Science Ventures (Germany); IKB Deutsche Industriekreditbank AG (Germany); tbg Technology Beteiligungsgesellschaft der Deutschen Ausgleichbank (Germany); Biotechnology Investments Ltd. [now being transferred to 3i Bioscience Investment Trust plc (UK)]; KB Lux Venture Capital Fund (Luxembourg); S d Venture Capital Investition (Germany); and several private investors
BioStratum Inc. Research Triangle Park, N.C. 3/27 $28 BioStratum raised $28M in a private placement that attracted new and previous investors from the U.S. and Europe; investors included HealthCap (Sweden); Equity Resources Group (U.S.); BankInvest (Denmark); Mellon Holdings Ltd. (UK); and MP Bio hf (Iceland)
Cepheid Sunnyvale, Calif. 3/6 $19.10 Cepheid raised $19.1M from corporate and individual investors in a Series C round led by Wheatley Partners II LP; new investors include Palladin Group, Merlin Biomed Group, Formula Growth Ltd., R.H. Capital Partners LLC and GBC North American Growth Fund Inc.; previous investors that participated include Invemed Associates Inc., Innogenetics NV, Medtronic Inc., and Advanced Technologies Ventures
Ciphergen Biosystems Inc. Palo Alto, Calif. 3/17 $28.60 Ciphergen sold 10.4M shares of Series E preferred stock for an aggregate purchase price of $28.6M; new investors include Atlas Venture (lead), Morgan Stanley Ventures, Essex Ventures, AP Asset Management and Orbimed Advisors; previous investors that participated in this round include Falcon Technology Partners, MDS Capital Corp. and S.R. One Ltd.
Genaissance Pharmaceuticals Inc. New Haven, Conn. 3/14 $60 Genaissance raised $60M in two rounds (B and C) of financing; new investors include Canaan Partners, A&A Actien Bank, Alta Partners, Chase Capital Partners, Johnson & Johnson Development Corp., Lombard Odier & Cie, and Sofinov; previous investors that participated include Biomedicine, Dresdner Kleinwort Benson, and Connecticut Innovations Inc.; the financings consisted of a $48M Series B round and a $12M Series C round
Genomica Corp. Boulder, Colo. 3/14 $15 Genomica raised $15M in a private placement of Series C preferred stock to institutional and accredited investors
Genteric Inc. Alameda, Calif. 3/29 $9 Genteric raised over $9M in a Series A financing; Alta Partners, MedVenture Associates and Sanderling participated, along with several individual investors
Kinetek Pharmaceuticals Inc. Vancouver, B.C. 3/4 C$20.1 (US$13.84) Kinetek raised C$20.1M (US$13.84M) in the second stage of its current round of financing; investors were led by Ontario Teachers Pension Plan, Royal Bank Ventures Inc., Ventures West B.C. Technology Investment Fund and the Working Opportunity Fund; other participants include RT Capital, Trian Equities, FutureFund Capital Corp., T2C2 Limited Partnership, Navigator Canadian Technology Fund, and Societ Innovatech du Grand Montreal, as well as U.S. and Canadian private parties; the first stage of the financing raised C$7.9M (US$5.44M)
LifeSpan BioSciences Inc. Seattle 3/8 $13.50 LifeSpan received $13.5M from undisclosed investors
Metabolex Inc. Hayward, Calif. 3/7 $10.75 Metabolex raised $10.75M in a financing led by John Hancock Life Insurance Co.; other participants are Pictet & Cie (Switzerland), the Acorn USA Fund of Wanger Asset Management, Lombard Odier (Switzerland), and Bay City Capital (which also acted as adviser)
NeuColl Inc. (subsidiary of Cohesion Technologies) Palo Alto, Calif. 3/7 $4 Cohesion's osteobiologics subsidiary garnered $4M in a private placement financing made by Stephens Group Inc.; Cohesion's stake is now under 50%
Neurotrophic Bioscience Inc. Toronto 3/24 $0.50 Neurotrophic completed a $0.5M leasing line with Transamerica Commercial Finance Corp.; agreement allows the company to convert existing equipment as well as to buy new equipment using the line
Promix Pty Ltd. Brisbane, Australia 3/22 A$3 (US$1.83) Promix raised A$3M (US$1.83M) from Start-Up Australia and Rothschilds Bioscience Managers
Proneuron Biotechnologies Ltd. Ness-Ziona, Israel 3/15 $3.70 Israel Infinity Venture Capital invested $0.75M in the round; other investors include D.S. Polaris Ltd., Hudson Investment Group, and Giza Venture Capital (Israel) (3/15)
Proteome Inc. Beverly, Mass. 3/1 $8.10 Proteome raised $8.1M from Boston Millennia Partners and William Blair Capital Partners LLC
Quorex Pharmaceuticals Inc. Carlsbad, Calif. 3/13 $1.10 Quorex completed its $2.2M seed financing with an additional $1.1M; investors include Johnson & Johnson Development Corp., Tullis-Dickerson & Co. Inc., IngelWood Ventures, and private investor Michael Grantham (3/13)
Seattle Genetics Inc. Bothell, Wash. 3/14 $30 Seattle raised $30M in Series B financing led by Bank of America Ventures; other investors include Cascade Investment, Vulcan Ventures, Olympic Venture Partners, Sofinnova Ventures and Indosuez Ventures (3/14)
TranXenoGen Inc. Shrewsbury, Mass. 3/28 $1.50 TranXenoGen raised $1.5M in a Series C and D placement of preferred stock to existing private investors and institutions including WestLB Panmure
Variagenics Inc. Cambridge, Mass. 3/7 $20 Variagenics raised $20M in a self-managed private placement; new investors include CIBC Capital Partners (lead) and Essex Investment Management Co.; previous investors that participated include The Sprout Group, Atlas Venture, Oxford Bioscience Partners, Forward Ventures, and Advent International
Zyomyx Inc. Hayward, Calif. 3/7 $22 Zyomyx raised $22M in a placement of Series C preferred stock; new investors include eHealth Technology Fund, Burrill & Co., and Singapore BioInnovation of America; the financing also attracted previous investors Skyline Ventures, Alloy Ventures, Lombard Odier & Cie, and H&Q Capital Management Inc.
APRIL
AlphaGene Inc. Woburn, Mass. 4/11 $6.50 AlphaGene raised $6.5M in a private placement; details ND
Artemis Pharmaceuticals GmbH Cologne, Germany 4/5 DM36 (US$18) Artemis conducted a self-managed, oversubscribed financing of DM36M (US$18M) consisting of DM$26M (US$13M) in venture capital and DM10M (US$5M) in unsecured loans; new investors included 3i Group Investments LP (UK), which led the financing, Technology Partners (Germany), Oppenheim Investor (a subsidiary of Sal Oppenheim Jr. & Cie; Germany), Commerz Partners (a subsidiary of Commerce Bank; Germany) and Technomedia Capital Partners (subsidiary of Stadtsparkasse Koein; Germany); first-round investors who participated included International BM Biomedicine Holdings, Atlas Venture, Global Life Science Holding, Oxford Bioscience Partners and Advent International
Cogent Neuroscience Inc. Durham, N.C. 4/4 $15 Cogent completed a $15M oversubscribed private placement led by Franklin Street Partners; investors included The Wakefield Group, Intersouth Partners, Kitty Hawk Capital, Aurora Ventures, Cordova Technology Partners, Pacific Rim Ventures, TriState Investment Group and S.R. One
Delsys Pharmaceutical Corp. Princeton, N.J. 4/25 $26 Delsys completed an oversubscribed private placement of preferred stock led by Rothschild Asset Management s International Biotechnology Trust; the financing attracted new investor Star Ventures (Germany) and existing investors Healthcare Ventures, Rho Management, Hudson Trust, CenterPoint Ventures, Prism Venture Partners, and Johnson & Johnson Development Corp.
diaDexus Inc. Santa Clara, Calif. 4/11 $102.50 diaDexus raised $102.5M in a private placement of Series C preferred stock led by BA Venture Partners (venture partnership funded by Bank of America) and American Express Financial Corp.; Prudential Vector Healthcare Group acted as placement agent; begun in 1997 as a joint venture of Incyte Genomics (INCY) and SmithKline Beecham plc (UK; NYSE: SBH), diaDexus converted to a C corporation from an LLC with this financing
Exact Laboratories Inc. Maynard, Mass. 4/13 $32 Exact raised $32M in a Series D financing led by new investor DCF Capital; other new investors included Zesiger Capital LLC, Back Bay Consulting Group, Vulcan Northwest Ventures, Robertson Stephens, Paine Webber Inc. and Galleon Group; existing investors who participated included One Liberty Ventures, Greylock Management Corp., Highland Capital Partners, Ashford Capital Management, RS Investment Management, Mayo Foundation for Medical Education and Research, Boston University Community Technology Fund, HLM Management and CB Health Ventures
Genmab A/S (spin-off of Medarex Inc.) Copenhagen, Denmark 4/11 DKK35 (US$4.8) Genmab raised approximately DKK35M (US$4.8M); further details ND
MDS Proteomics Inc. (spin-off of MDS Inc.) Toronto 4/3 C$82.5 (US$56.9) MDS raised C$82.5M (US$56.9M) in a private placement of 3.3M special warrants at C$25 (US$17.24) each; the placement values the company at about C$600M (US$414M); underwriters were Canaccord Capital Corp., HSBC Securities Canada and Yorkton Securities Inc.
Nereus Pharmaceuticals Inc. San Diego 4/17 $8.60 Nereus completed an $8.6M first round of venture financing; Alta Partners and Forward Ventures led the round; other investors included GIMV, Jafco and Tech Amp International
NewBiotics Inc. San Diego 4/4 $6.30 NewBiotics raised $6.3M in a financing led by IngleWood Ventures and including investments from J.F. Shea Co., HMCH Ventures and Life Science Partners
Northwest Biotherapeutics Inc. Seattle 4/9 $5 Northwest raised $5M in a self-directed, oversubscribed private placement of 6% convertible promissory notes; notes and interest will convert to Series D convertible preferred stock at the lesser of $5 per share or the company s next equity round
Quantum Dot. Corp. Palo Alto, Calif. 4/6 $30 Quantum Dot completed a second-round financing, led by Schroder Ventures, a new investor; other new investors were Frazier & Co., MPM Asset Management and CMEA Ventures; they joined existing investors Institutional Venture Partners, Abingworth Management Ltd. and Technolgen Associates
Structural Bioinformatics Inc. San Diego 4/4 $32.60 Structural Bioinformatics raised $32.6M in a Series D preferred stock financing that was oversubscribed and led by Perseus-Soros BioPharmaceutical Fund LP; other participants included Invesco Capital Management Deutsche Vermogensbildungs GmbH (Germany; advised by AP Asset Management of Zurich), Veritas SG Investment Trust GmbH (Germany), Castle Rock Capital Management, New Medical Technologies (Switzerland), Dansk Kapitalanlaeg A/S (Denmark), and BioAsia Investments; ING Barings served as placement agents
Structural GenomiX San Diego 4/5 $32 Structural GenomiX raised $32M in a second round of venture financing led by Sprout Group and including new investors Lombard-Odier, Index Ventures and Vulcan Northwest, as well as existing investors Atlas Venture, Prospect Venture Partners and Apple Tree Partners
ViaCell Inc. Boston and Worcester, Mass. 4/12 $11 Concurrent with the merger of Viacord Inc. and t. Breeders Inc. to create ViaCell, the company raised $11M from a syndicate of three venture capital firms led by MPM Asset Management and including Javelin Capital and Zero Stage Capital
Xanthon Inc. Research Triangle Park, N.C. 4/11 $12 Xanthon completed a $12M Series D preferred stock financing; investors included Intersouth Partners, Noro-Moseley Partners, Franklin Street Partners, Cordova Technology Partners, the Aurora Funds, Centennial Venture Partners Fund, and The North Carolina Technology Development Authority
MAY
Acadia Pharmaceuticals Inc. San Diego 5/8 $15.50 Acadia completed a $15.5M private placement of preferred stock in a mezzanine round led by H&Q Healthcare Investors, H&Q Life Sciences Investors and OrbiMed Advisors LLC; other participants included The Kaufmann Fund and previous investors Dansk Kapitalanlaeg and Kommunernes Pensionsforsikring A/S (both of Denmark)
Athersys Inc. Cleveland 5/8 $47.50 Athersys raised $47.5M in a placement of Class F convertible preferred stock; investors included INVESCO Funds, Van Wagoner Funds, Crestwood Capital Partners, Cogene Biotech Ventures, Roxbury Capital, Chelsey Capital, KBC Equity Funds, MCP Global Corp., President Life Sciences, Manschot Opportunity Fund, TalMor Capital Management, Curran Partners, Emerging Growth Management and DRW Venture Partners
Biofrontera Pharmaceuticals GmbH Leverkusen, Germany 5/31 DM23 (US$11.5) Biofrontera completed oversubscribed placement led by 3i Group Investments LP and including Alta Vista Equity Partner GmbH & Co. KG (Germany), TRE Holding AG (Switzerland), Technologie-Beteiligungs-Gesellschaft der Deutschen Ausgleichsbank (Germany); first-round investors who participated included LeVenture and TechnoMedia (both of Germany)
BioNumerik Pharmaceuticals Inc. San Antonio, Texas 5/8 $12 BioNumerik raised more than $12M in a selfmanaged private placement
eBioinformatics Pleasanton, Calif. 5/26 $10 eBioinformatics raised $10M in second-round financing of Series C preferred stock; International Biotechnology Trust (UK) invested $3M as co-lead investor; other new investors were Colonial First State Private Equity and CSL Ltd; previous investors who participated included Rotschild's Australian Bioscience Trust, Allen & Buckeridge and 3i Bioscience Investment Trust
Entelos Inc. Menlo Park, Calif. 5/4 $14.60 Entelos raised $14.6M in a Series B financing led by Abingworth Management; new investors were St. Paul Ventures and Boulder Ventures; previous investors Brentwood and Charles River Ventures also participated
Eurogene Ltd. London 5/24 15 (US$22) Eurogene raised 15M (US$22M) in secondround financing
GeneMachines San Carlos, Calif. 5/3 $10.70 Gene Machines raised $10.7M in a Series B preferred stock financing co-led by Oxford Bioscience Partners III L.P. and Frazier & Co., each of which invested $5M
GeneTrol Biotherapeutics Inc. Oakland, Calif. 5/15 $3.90 GeneTrol raised $3.9M in second-round financing led by Fortune Consulting Group (Taiwan); other investors include CYPAC Investment Management Ltd., Global Ventures, First BioVenture Capital, Asia Pacific Holdings Corp., and Pacific Venture Capital Co. Ltd. (all of Taiwan), and Creative Assets Ltd. (Hong Kong)
HepaVec AG Berlin 5/8 DM8 (US$3.7) Techno Venture Management led this secondround financing, which attracted previous investors Dansk Kapitalanlaeg (Denmark) and Alpinvest International NV (the Netherlands); they were joined by new investors Industrie Management Holding GmbH (Germany) and KB Lux Venture Capital Fund (Luxembourg)
ImmGenics Pharmaceuticals Inc. Vancouver, British Columbia 5/16 C$9 (US$6) ImmGenics netted C$9M (US$6M) in a placement of preferred equity with Nomura International plc and International Biotechnology Trust (managed by Rothschild Asset Management Ltd.)
Morphotek Inc. Philadelphia 5/22 $2 Morphotek received $2M in seed financing led by Allan Bedwick, president of Bedwick Capital Management
Novocell Inc. Irvine, Calif. 5/16 ND Novocell completed a Series B financing led by BD Ventures LLC, a venture capital fund sponsored by Becton, Dickinson and Co.
Oxxon Pharmaccines Ltd. London 5/17 1.1 (US$1.6) Oxxon raised 1.1M (US$1.6M) in a first-round financing with MVM Ltd. and Neomed Management
Pharmadigm Inc. Salt Lake City 5/2 ND Pharmadigm completed the first of two closings on a $12M Series E convertible preferred stock offering with Friedli Corporate Finance (Switzerland) and an existing shareholder; final closing is slated for 6/30
Repair Inc. Boston 5/31 $2 Repair raised $2M in seed financing; founders and investors include Maine Medical Center and Masthead Venture Partners
Xenogen Corp. Alameda, Calif. 5/18 $30.50 Xenogen raised $30.5M in a mezzanine round that attracted new investors HSBC Investment Bank plc (UK), Lombard Odier & Cie (Switzerland), Pictet & Cie Banquiers (Switzerland), and Chevron Technology Ventures (subsidiary of Chevron Corp.); previous investors provided $11M; they included Brentwood Associates, Delphi Ventures, Harvard Private Capital Holdings, S.R. One Ltd., and Invemed Fund; Bay City Capital advised Xenogen
JUNE
454 Corp. (majority-owned subsidiary of CuraGen Corp.; CRGN) New Haven, Conn. 6/1 $32.50 CuraGen launched 454 Corp. as a majority-owned subsidiary, with private placement funding of $32M; investors include Soros Fund Management LLC and Cooper Hill Partners LLC
Acadia Pharmaceuticals Inc. San Diego 6/20 $6.50 Acadia raised an additional $6.5M in mezzanine round, in addition to $15.5M raised 5/00; investors in the second closing were Pacific Rim Ventures Ltd. and current investors LonmodTagernes Dyrtidsfond, Dansk KaptalanLaeg Aktieselskab and Kommunernes Pensionsforsikring A/S; investors who participated in both closings included H&Q Healthcare Investors, H&Q Life Sciences Investors, OrbiMed Advisors LLC and the Kaufmann Fund
BioAlliance Pharma SA Paris 6/8 EUR7 (US$6.7) BioAlliance raised EUR7M (US$6.7M); investors include 3i, Capricorn Ventures, Technolife 2010, SPEF and ABN AMRO; Sitka Partners advised
Ecogenix Inc. Montreal 6/28 C$0.5M (US$0.34) T2C2/Bio Ltd. Partnership will invest C$0.4M (US$0.27M) per year and SignalGene Inc. (TSE:SGI) will invest C$0.1M (US$0.067M) per year in the newly formed company, the result of a partnership between SignalGene and Sainte Justine Hospital
Ecopia BioSciences Inc. Montreal 6/15 C$10 (US$6.8) Ecopia raised C$10M (US$6.8M) in second of two private placements, the first of which was conducted with parent firm Theratechnologies; Yorkton Securities led the financing
EyeTech Pharmaceuticals Inc. New York 6/15 $34 EyeTech raised $34M in initial round of financing led by Schroeder Life Sciences; Merrill Lynch participated
GeneEd Inc. San Francisco 6/26 $2 GeneEd raised $2M in seed round; principal investors include Incyte Genomics, Alza Pharmaceuticals and the law firm of Wilson Sonsini Goodrich & Rosati
GenMab A/S Copenhagen, Denmark 6/13 $40.50 GenMab raised $40.5M in a financing led by Index Ventures; new investors include Apax Europe IV and Lombard Odier Immunology Fund; existing investors include BankInvest, Lonmodtagernes Dyrtidsfond, A/S Dansk Erhvervinvestering, and Medarex Inc. (MEDX)
GenOdyssee Paris 6/14 EUR8 (US$7.7) GenOdyssee raised EUR8M (US$7.7M) in an initial funding round led by Matignon Investissement and including Societe Generale Asset Management, Technolife 2010 and Georges Cohen (chairman of the French computer software company Transiciel)
Inhibitex Inc. Alpharetta, Ga. 6/14 $15 Inhibitex raised $15M in a Series C financing round of convertible preferred stock; the round was led by William Blair Capital Partners VI LLC; new investors include Pacific Horizon Investors and Oakwood Medical; the financing also attracted previous investors Alliance Technology, Cordova Ventures and the AM Fund
Maxia Pharmaceuticals Inc. San Diego 6/1 $10.25 Maxia raised $10.25M in first closing of a placement of Series B preferred stock and convertible debt led by AP Asset Management AG and Bay City Capital (which also acted as placement agent); Maxia is seeking to raise an additional $10.25M in the round
Neuronyx Inc. Malvern, Pa. 6/13 $6 Neuronyx raised $6M in a Series A financing whose participants included Neose Technologies Inc. (NTEC)
Paratek Pharmaceuticals Inc. Boston 6/27 $20 Paratek raised $20M in a private placement that attracted new investors Lombard Odier, BankInvest, BioFund, FSC Corp. and Nomura International plc (which also acted as international placement agent)
ValiGen NV Paris and Newtown, Pa. 6/8 $25 ValiGen raised $25M in a private placement that attracted new and previous investors from the U.S. and Europe; investors include International Biotechnology Trust and ImClone Systems (IMCL)
JULY
Adolor Corp. Malvern, Pa. 7/11 $36.60 Adolor raised $36.6M in a private placement of preferred stock led by new investor MPM Capital; other new investors included Sprout Group, Zesiger Capital Group, Lombard Odier & Cie and Special Situations Funds; previous investors who participated included Alta Partners, ARCH Venture Partners, OrbiMed Advisors, S.R. One Ltd. and TL Ventures; Pacific Growth Equities Inc. managed the offering
AlphaVax Inc. Durham, N.C. 7/24 $11 AlphaVax raised $11M in a private placement of Series C convertible preferred securities; Burton Advisers Ltd. acted as placement agent and financial adviser
Arrow Therapeutics Ltd. London 7/6 11.1 (US$16.75) Arrow raised 11.1M (US$16.75M) in a second venture financing led by GIMV, which invested 2.75M (US$4.15M); three other investors Alta Partners, TVM Techno Venture Management and 3i each invested 2.25M (US$3.4M); Northern Venture Managers invested 1M (US$1.51M); existing investors, including Unibio Ltd. and founding scientists, committed another 0.6M (US$0.9M)
Circassia Ltd. London 7/24 0.245 (US$0.37) Circassia raised 0.245M (US$0.37M) in seed funding from the Challenge Seed Fund, set up by the UK government and the Wellcome Trust
Compugen Ltd. Tel Aviv and Jamesburg, N.J. 7/19 $35.40 Compugen netted $35.4M in a private placement led by Apax Partners & Co. and Pequot Private Equity Group; new investors also included venture capital funds from the Giza Group, Yozma Venture Fund and State Farm Mutual Automobile Insurance Co.; they were joined by previous investors including Clal Biotechnology Industries Ltd., Apax Partners Israel, Poalim Investments Ltd., STI Venture Fund Ltd., and Ampal Industries Ltd.
Cytos Biotechnology AG Zurich, Switzerland 7/25 CHF50 (US$32) Cytos raised CHF50M (US$32M) in independently managed second-round financing; participants included previous investors Global Life Sciences, Innoventure (subsidiary of Credit Suisse) and Novartis; the round also drew new investors Alta Partners, Aventic (subsidiary of UBS), Health Cap, Lombard Odier, New Medical Technologies and Private Equity Direct Finance (subsidiary of Bank Vontobel)
Dov Pharmaceutical Inc. Hackensack, N.J. 7/6 $7 Dov completed a Series C convertible preferred stock financing led by The Biotechnology Value Fund LP, its affiliates and investment funds managed by Reservoir Capital Group LLC; Aurora Capital LLC served as placement agent
Enanta Pharmaceuticals Inc. Cambridge, Mass. 7/28 $20 Enanta raised $20M in a second-round financing that included Oxford Bioscience Partners (lead), Advent International, TVM Techno Venture Management, Caduceus Capital, Bank Vontobel, Alpinvest International BV and KB Lux Venture Capital
Fluorous Technologies Inc. Pittsburgh 7/6 ND Fluorous' initial investors included Albany Molecular Research Inc. (AMRI), which provided $0.65M, Alfred Bader (retired founder of Aldrich Chemical Co.) and the University of Pittsburgh (7/6)
Framingham Genomic Medicine Inc. Boston 7/10 $6 Framingham raised the first $6M in first round of financing, led by Oxford Bioscience Partners, Venrock Associates and S.R. One Ltd.
Geneva Proteomics Inc. Evanston, Ill., and Geneva, Switzerland 7/17 $40 Geneva raised $40M in a first-round financing whose participants included funds and accounts managed by Fidelity Management & Research Company, Jennison Associates LLC, Merlin BioMed Group, OrbiMed Advisors LLC, CEH Geneve and Basellandschaftlich Pensionkasse
Innate Pharma SAS Marseille, France 7/26 FFr30 (US$4.5) Innate raised FFr30M (US$4.5M) from Sofinnova, Auriga and GIMV
Metabasis Therapeutics Inc. San Diego 7/18 $13 Metabasis raised $13M in a private placement of preferred stock with MPM Capital Management and Interwest Partners; financing is the first round for the company since its 6/99 spinoff from Sicor Inc.
NeuroSurvival Technologies Ltd. Petach-Tikva, Israel 7/26 $7.50 NeuroSurvival completed a second round of financing; participants included Johnson & Johnson Development Corp., Bargal R&D Ltd., Clal Biotechnology Industries Ltd., Federman Holdings Ltd., Modgal-Tech Ltd., Palim Investments Ltd., and Technorov Holdings Ltd.
Physiome Sciences Inc. Princeton, N.J. 7/17 $50 Physiome raised $50M in a round led by Investor AB (through Investor Growth Capital) and Dresdner Kleinwort Benson; other new investors included OrbiMed Advisors LLC, Lombard Odier et Cie and CIT Group; Muzinich & Co. acted as placement agent (7/17)
RiboTargets Ltd. Abingdon, UK 7/19 6 (US$9) RiboTargets raised 6M (US$9M) in a private financing that attracted previous investors Apax Partners, 3i plc, Advent Venture Partners and Kargoe; they were joined by new investors NIB Capital, Rendex and Quester
Sunesis Pharmaceuticals Inc. Redwood City, Calif. 7/11 $60 Sunesis raised $60M in a Series C preferred stock financing led by CSFB Private Equity; new investors were International Biotechnology Trust (managed by Rothschild Asset Management) and Lombard Odier & Cie; previous investors who participated were E.M. Warburg, Pincus & Co. LLC, Mayfield Fund, Venrock Associates and Abingworth Management; a group of individuals also invested; Broadview Ltd. acted as adviser and placement agent for a portion of the financing
Third Wave Technologies Inc. Madison, Wis. 7/26 $48 Third Wave raised $48M in a private round led by BB Biotech and including new investors Janus Capital, Putnam Investments, American Express, Scudder Funds, Invesco Funds Group, Tisch Family Interests, Essex, Galleon Investments, CIBC Capital Partners and Jennison Capital; previous investors who participated included The Wellcome Trust, Schroder Ventures, The Burrill AgBio Capital Fund, UK Medical Ventures, Venture Investors of Wisconsin and Wisconsin Alumni Research Foundation
Zycos Inc. Cambridge, Mass. 7/10 $30.40 Zycos raised $30.4M in a private placement of preferred stock led by Dresdner Kleinwort Benson and William Blair Capital Partners; other participants included new investors Stephens Inc., Sofinov, Oakwood Medical Investments and Medical Venture Partners; the financing also attracted existing investors Lombard Odier and New Medical Technologies
AUGUST
Active Pass Pharmaceuticals Inc. Vancouver, British Columbia 8/4 C$5 (US$3.37) Active Pass concluded a financing of C$5M, led by the Western Technology Seed Investment Fund, and jointly managed by Ventures West, Cascadia Pacific and the Business Development Bank of Canada; investors included Working Opportunity Fund and Navigator Canadian Technology Fund, as well as new investors Future Fund Capital Corp., BioFuture Fund Capital Corp., and a group of individual investors
AeroGen Inc. Sunnyvale, Calif. 8/9 $16.90 AeroGen completed a $16.9M private placement; existing investors included CMEA, Wheatley Partners, Invesco Funds Group Inc., Viridian Capital and Interwest Partners; new investors included MVI Medical Venture Investments Limited, The Kaufmann Fund and Hunt Ventures LP
Arakis Ltd. Cambridge, UK 8/29 4 (US$6.01) Arakis raised 4M from MB Venture Capital Fund I and the Merlin Biosciences Fund, 2M from each; the financing will be made in two tranches, one immediately and one Feb. 2001
Atairgin Technologies Inc. Irvine, Calif. 8/23 $7.20 Atairgin completed a private placement Series D round of financing totaling $7.2M; investors included Fremont Ventures and new investors LabInvest Associates Inc. and Oakwood Medical Investors of St. Louis
BioQuest Inc. Houston 8/25 $3 BioQuest closed an initial $3M investment by Merck Finck & Co.; the investment is part of a private placement of up to $6M in Series A 8% convertible preferred stock; the stock is convertible at $4 per share and each share will be accompanied by one half a warrant to purchase a share at $5
CombiMatrix Corp. Snoqualmie, Wash. 8/3 $36 CombiMatrix raised $36M in a private financing; investors included Acacia Research, Emerging Growth Management, JDS Capital, OrbiMed Advisors, Oracle Partners, SAC Capital Management, Seneca Capital and Wheatley Partners, among others
Cytos Biotechnology AG Zurich, Switzerland 8/2 CHF50 (US$32) Cytos received CHF50M (US$32M) in a second round of venture capital financing
Elitra Pharmaceuticals Inc. San Diego 8/23 $22 Elitra completed a $22M preferred stock financing, its third round with financial investors
Evolutec Ltd. Oxford, England 8/16 2.7 (US$4) Evolutec raised 2.7M (US$4M) in its second round of fund raising
Graffinity Pharmaceutical Design GmbH Heidelberg, Germany 8/16 DM50 (US$23.2) Graffinity raised DM50M (US$23.2M) in a second-round funding
Hyalose LLC Oklahoma City 8/25 $0.15 Hyalose received a $150,000 commitment from the Oklahoma Center for the Advancement of Science and Technology
Integrative Proteomics Inc. Toronto 8/17 US$8 Integrative Proteomics completed an initial US$8M equity financing, involving a range of U.S., European and Canadian investors; investors included Lombard Odier Immunology Fund and CC Capital Partners Inc.
MorphoChem AG Munich, Germany 8/2 EUR40.7 (US$37.5) MorphoChem raised $37.5M as part of a third-round private placement; investors included Techno Venture Management, Alta Partners, IKB Venture Capital, Alta Berkeley, Domain Associates and 3i Bioscience Investment trust; new investors, led by Merlin BioSciences, included Nomura International, Julius Bar, West LB and Viscardi, as well as private investors
MorphoGen Pharmaceuticals Inc. San Diego 8/23 MorphoGen received its initial round of equity funding, raising an undisclosed amount
NeuralStem Biopharmaceuticals Ltd. College Park, Md. 8/8 $5 NeuralStem completed a $5M Series B financing from SJRJ LLC, an investment company
Panacea Pharmaceuticals Inc. Rockville, Md. 8/3 Panacea closed its initial round of financing, raising an undisclosed amount
Revotar Biopharmaceuticals AG Berlin 8/1 DM30 (US$14.2) Texas Biotechnology Corp. entered into an agreement for the initial financing of its German subsidiary, Revotar Biopharmaceuticals AG, with equity investments by bmp AG and Mediport AG; Revotar raised DM10M in equity and has in place funding through government grants and loans expected to increase start-up funding to DM30M
Syrrx Inc. San Diego 8/3 $5.07 Syrrx completed a $5.07M Series A round of venture financing; participants included Bay City Capital, Chemicals and Materials Enterprise Associates, MPM Asset Management, and Versant Ventures
Targacept Inc. Winston-Salem, N.C. 8/24 $30.40 Targacept completed a $30.4M private placement; the lead investor was Euclid SR Partners; other investors were Burrill & Co., Advent Venture Partners, Auriga Ventures, CDC Innovation, Genavent, Societe Generale Asset Management Finance and Longleaf Venture Fund
Xcyte Therapies Inc. Seattle 8/16 $28 Xcyte closed a $28M Series D equity financing; investors included Alta Partners, ARCH Venture Partners, Falcon Technology Partners, Fluke Capital Management, The Sprout Group/DLJ, Tredegar Investments and Vulcan Northwest; new investor MPM Capital led the round, with additional funding from Vector Fund Management and MGN Opportunity Group
Xenova Group plc Slough, UK 8/4 $11.70 Xenova received payment for 1.5M units offered under the open offer for 2.89M units at 345 pence (US$5.18) per unit; the remaining 1.4M units will be taken up by investors pursuant to the placing by Nomura International plc
SEPTEMBER
Atrium Biotechnologies Inc. Quebec City, Quebec 9/6 C$10 (US$6.75) AEterna Laboratories Inc. (AELA) announced that SGF Soquia Inc., Fonds de solidarite FTQ and Fonds d investissement bio-alimentaire acquired 1M shares in its privately held subsidiary, Atrium
BioWisdom Ltd. Cambridge, UK 9/11 US$2.8 Company completed a first round of financing with MB Venture Capital for US$2.8M
Dynavax Technologies Corp. Berkeley, Calif. 9/26 $22.60 Company completed a $22.6M private placement of preferred stock; investors included Alta Partners, Axiom Venture Partners, BA Venture Partners, Biotechvest LP, Forward Ventures, InterWest Partner, Sanderling, bioMerieux Alliance SA, China Development Industrial Bank, JAFCO, Phillips Capital Management and Finedix BV, as well as various individuals
Eos Biotechnology Inc. South San Francisco 9/28 $27.50 Eos completed a $27.5M private placement of preferred stock; investors included Affymetrix, Biogen, Medarex, U.S. Bancorp Piper Jaffray, Robertson Stephens and other existing investors
ExonHit Therapeutics Paris 9/5 EUR13.9 (US$12.4) ExonHit raised EUR13.9M in private equity with investors AGF Private Equity, BNP Private Equity, Oxford Bioscience, Sofinnova Partners and CDC Innovation
FibroGen Inc. South San Francisco 9/28 $56.50 Company completed a $56.5M private placement of convertible preferred stock; investors included a syndicate representing Finland, Japan, Taiwan and current stockholders and were led by Franklin Templeton Investments and America Express Financial Advisors
Hypnion Inc. Worcester, Mass. 9/26 $10.40 Hypnion raised $10.4M in private equity financing led by Oxford Bioscience Partners; investors also included AGTC Funds and GIMV
Immunicon Corp. Huntingdon Valley, Pa. 9/11 $21.75 Immunicon completed a $21.75M private offering of convertible preferred equity; Canaan Partners and Foundation Medical Partners led the financing, which included MDS Capital Corp., TL Ventures, Anthem Capital, Johnston Associates, Johnson & Johnson Development Corp., LHC Corp. and MedCapital
Ingenium Pharmaceuticals AG Martinsried, Germany 9/11 EUR50 (US$43.1) Ingenium completed a EUR50M private placement; the investment was led by Schroder Ventures and Sofinnova Partners, and included Polaris Venture Partners, Lehman Brothers, Index Ventures, Deutsche Bank, Sal. Oppenheim, IKB, New Medical Technologies, tbg, Bayern Kapital, TVM and Alpinvest
NeuralStem Biopharmaceuticals Ltd. College Park, Md. 9/27 $0.50 Company announced a $500,000 investment from the state of Maryland s Enterprise Investment Fund
Neurotrophic Bioscience Inc. Toronto 9/12 C$6 (US$4) Company completed a second round of financing from its existing investors, Business Development Bank of Canada, GeneChem Technologies Venture Fund LP and Sofinov
Novazyme Pharmaceuticals Inc. Oklahoma City 9/18 $8 Novazyme completed an $8M equity financing through the private placement of Series A preferred stock; the placement was co-led by Catalyst Health & Technology Partners, HealthCare Ventures and Perseus-Soros Biopharmaceutical Fund
Panacea Pharmaceuticals Inc. Rockville, Md. 9/27 ND Company announced the completion of its Series A round of financing, which was oversubscribed
PTC Therapeutics Inc. South Plainfield, N.J. 9/26 $15 Company received $15M in a financing led by Vulcan Ventures Inc., CSFB Private Equity and New Medical Technologies
Senomyx Inc. La Jolla, Calif. 9/14 $10 Senomyx completed a $10M private placement of Series B preferred stock; the financing was led by Alejandro Zaffaroni and included the Baker Tisch Investments LLC, Bay City Capital, Domain Associates, Prospect Ventures, Kingsbury Capital Partners and Rho Management
Signature BioScience Burlingame, Calif. 9/6 $17 The financing was led by Atlas Venture of Boston, and included CIBC Capital Partners, Coral Ventures, Prospect Venture Partners and Abingworth Management
Structural GenomiX San Diego 9/20 $45 Structural GenomiX completed a $45M round of private equity financing led by BA Venture Partners; other investors included Amerindo, MDS Health Ventures, OrbiMed Advisors, Vector Fund Management, Atlas Ventures, Apple Tree Partners, The Sprout Group, Index Ventures and Vulcan Northwest; S.G. Cowen served as placement agent
TransMolecular Inc. Birmingham, Ala. 9/14 $9 TransMolecular completed a $9M Series B financing led by TVM Techno Venture Management GmbH; the financing included Tullis-Dickerson & Co. Inc., President Life Sciences Co. Ltd., Pacific Horizon Partners III, Portrush Group and Suttle Brothers Investments
OCTOBER
AviGenics Inc. Athens, Ga. 10/24 $10 AviGenics raised over $10M in its second venture capital financing with the private placement of preferred stock to institutional investors; Stephens Group Inc. acted as the lead investor; investors included T.D. Javelin, Cordova Technology Partners and Kitty Hawk Capital, as well as T.D. Lighthouse, Fuqua Ventures and two large private investment funds
Cellomics Inc. Pittsburgh 10/16 $30 Cellomics completed a private placement of Series C preferred stock, raising $30M; the placement was led by a group of funds managed by Amerindo Investment Advisors; new investors included Invesco Global Health Sciences Fund, Alta Partners, Burrill Biotechnology Capital Fund, BayStar Capital, Ariane Health Fund, LCF Rothschild and Biosphere Existing Investors, as well as InterWest Partners and Vector Fund Management
Diatos SA Paris 10/17 US$13.2 Diatos raised US$13.16M through an international private financing co-led by GIMV and InterWest Partners; it included Societe Generale Asset Management, AGF Private Equity, Sopartec and Sofinnova Partners
FeRx Inc. San Diego 10/23 $6.10 FeRx completed a Series C private round of financing, raising $6.1M; investors included Brentwood Venture Capital, Whittier Ventures LLC, California Technology Venture Partners and several Canadian institutional investors arranged through Jennings Capital
Galileo Laboratories Inc. Santa Clara, Calif. 10/31 $31 Galileo raised $31M in a third-round venture financing; investors included North Castle Partners, H&Q Life Sciences, H&Q Healthcare, Sofinov, The Chatterjee Group, Alloy Ventures, Brinson Partners, Bay City Capital and CMEA Life Sciences
GeneFormatics Inc. San Diego 10/6 $15 GeneFormatics raised $15M in a Series B financing led by the Perseus-Soros BioPharmaceutical Fund LP, Merrill Lynch Ventures, OrbiMed Advisors and GeneChem Management, as well as Burrill & Co., IngleWood Ventures and Moss Forest Venture
Genomics Collaborative Inc. Cambridge, Mass. 10/11 $36 The financing was led by Invesco Private Capital and included Whitney & Co., Applied Genomic Technology Capital Funds, Oracle Partners, the Economic Development Board, and others
Hybrigenics SA Paris 10/3 EUR19.5 (US$17.3) Hybrigenics raised US$17.3M in a private placement; investors included Apax Partners, Auriga, IMH, HealthCap, Alafi Capital, Lombard Odier, Rendex NV, Sofindev and Medicis AG
Hypnion Inc. Worcester, Mass. 10/5 $10.40 Hypnion raised $10.4M in a Series A private equity financing; Oxford Bioscience Partners led the financing, along with Applied Genomic Technology Capital Fund LP and GIMV
MethylGene Inc. Montreal 10/4 $18.60 MethylGene completed a new round of private funding, raiding $18.6M; investors included Fonds de solidarite FTQ, Sofinov, GeneChem Technologies Venture Fund LP, Canadian Medical Discovery Fund Inc., Royal Bank Capital Partners and Investissement BioCapital Inc.
Neurome Inc. La Jolla, Calif. 10/20 $9 Neurome raised $9M in initial financing; investors included Digital Gene Technologies, Elan Corp. plc and a group of private biotech investors; initial shareholders also include The Scripps Research Institute, Mount Sinai School of Medicine and company founders Floyd E. Bloom, John H. Morrison and Warren G. Young
Ontogen Corp. Carlsbad, Calif. 10/13 $16.40 Ontogen completed a $16.4M private placement through the sale of its Series D preferred stock; investors included Lombard Odier & Cie and the Johnson & Johnson Development Corp.
Provalis plc Deeside, Wales 10/25 10.8 (US$15.6) Provalis share placing and open offer raised US$15.6M after expenses
Renovo Ltd. London 10/25 8 (US$11.6) Renovo, a spinout from Manchester University, raised US$11.6M in its first round of funding to develop treatments to prevent scarring and accelerate wound healing
SemBioSys Genetics Inc. Calgary, Alberta 10/20 C$16.6 (US$10.9) SemBioSys completed a C$16.56M private placement of Series A preferred stock; the financing was led by Bay City Capital LLC and included Ventures West, the Business Development Bank of Canada and Royal Bank Capital Partners.
StemCo Biomedical Inc. Durham, N.C. 10/18 $4 StemCo closed on a first round of venture capital financing of $4M; Intersouth Partners led the investment with participation from The Aurora Funds
Syrrx Inc. San Diego 10/3 $20 Syrrx completed a $20M Series B round of venture financing; placement was led by MPM Asset Management and included Versant Ventures, Chemicals and Materials Enterprise Associates, Bay City Capital, Lombard Odier & Cie and Alejandro Zaffaroni
Zarix Inc. Berwyn, Pa. 10/4 $24 Zarix closed a private placement of Series C convertible preferred shares, raising $23.5M; Investors included Sofinov, the Ontario Teacher s Pension Plan, BioAsia Investments LLC, EJ Financial Enterprises Inc., the New York Life Insurance Co. and Veron International
ZymoGenetics Inc. Seattle 10/23 $150 Novo Nordisk AS (Denmark; NYSE:NVO) took steps to establish its fully owned subsidiary as an independent corporate entity by signing a $150M private placement into ZymoGenetics from an international investor consortium led by E.M. Warburg, Pincus & Co. LLC
NOVEMBER
Achillion Pharmaceuticals Inc. New Haven, Conn. 11/22 $6.50 Achillion raised $6.5M in venture funding supplied by Schroder Ventures, Atlas Venture and Advent International, as well as Connecticut Innovations Inc.
Adherex Technologies Inc. Ottawa, Ontario 11/7 C$10.3 (US$6.73) Adherex completed a $6.73M financing, its final round before going public with an IPO targeted for February
Artecel Sciences Inc. Durham, N.C. 11/28 $4 Artecel completed a $4M first-round financing, led by Eno River Capital LLC; other investors included TriState Investment Group IV LLC, BioWorld Venture Capital Corp., Fujisawa Investments for Entrepreneurship LP, and several individual investors
Arpida Ltd. Munchenstein, Switzerland 11/8 CHF40 (US$22.6) Apida raised US$22.6M in its second round of funding
Arradial Inc. Boston 11/17 $3 Arradial completed an initial venture capital financing of $3M; the round was led by Oxford Bioscience Partners and included an investment from Boston University s Community Technology Fund
Big Bear Bio Inc. Austin, Texas 11/22 $5.10 Big Bear Bio raised $5.1M in its first round of financing; the round was led by Life Science Venture Fund
CellFactors plc London 11/29 1.6 (US$2.3) CellFactors raised US$2.3M in a seed-funding round
Coley Pharmaceutical Inc. Wellesley, Mass. 11/1 $60 Coley completed a $60M international private financing led by DWS Investment GmbH; investors included DVG, Commerzbank Private Equity, Robertson Stephens Bayview 2000, Global Life Science Partners, Techno Venture Management, Quiagen NV, Alpinvest Holding N.V. and Alafi Capital
Cytokinetics Inc. South San Francisco 11/22 $55 Cytokinetics raised $55M in its third round of private financing; investors included Mayfield Fund, Vulcan Ventures Inc., Sevin Rosen Funds, CSFB Private Equity, Alta Partners and Lombard Odier & Cie
Cytovax Biotechnologies Inc. Edmonton, Alberta 11/1 C$7.9 (US$5.1) Cytovax sold more than 1.9M special warrants in September and October; Acumen Capital Finance Partners Ltd. and Goepel McDermid Inc. acted as agents
Cytran Inc. Kirkland, Wash. 11/10 $17 Cytran closed a $17M private placement of convertible debentures; the round included lead investments by Alza Corp. and Stephens Group Inc.
Epigenomics AG Berlin 11/14 EUR28 (US$24) Epigenomics completed a second-round financing totaling EUR28M; investors included Deutsch Venture Capital Gessellschaft and a number of new investors from the international investment community, including MPM Asset Management, 3i and Abingworth Management
Immuno-Designed Molecules SA Paris 11/20 EUR48.9 (US$41.6) Immuno-Designed Molecules completed its third round of financing from private investors; the round was led by Fortis Bank
Islet Technology Inc. St. Paul, Minn. 11/30 $1.75 Islet raised $1.75M in a private placement equity financing; Peterson Brothers Securities Co. assisted with a portion of the financing
Kreatech Biotechnology BV Amsterdam 11/9 US$3.41 Kreatech raised US$3.41 in a private placement of stock with Alafi Capital and Life Sciences Partners; Bank Ten Cate & Cie NV led the round
Locus Discovery Inc. Princeton, N.J. 11/28 $42.75 Locus raised $42.75M in its second round of private equity financing through the issuance of preferred stock; the round was led by Cooper Hill Partners and included Origin Capital, Amerindo Investment Advisers, Invesco Global Health Sciences Fund, Prism Venture Partners, Dresdner Klienwort Benson, Delphi Ventures, Johnson & Johnson Development Corp., Tredegar Investments and ReqMed Co., among others
Microbia Inc. Cambridge, Mass. 11/2 $23 Microbia raised $23M in a second round of private equity financing; investors included BancBoston Ventures, Essex Investment Management Co., Venrock Associates, Polaris Venture Partners, Aberdare Ventures and numerous others
MelTec GmbH Magdeburg, Germany 11/20 DM38 (US$16.5) MelTec completed its initial round of financing led by Volksbank Magdeburg and the community task program of Saxony-Anhalt
MMI Group plc Cambridge, UK 11/8 3.5 (US$5) MMI raised US$5M to fund its international expansion
Novelos Therapeutics Inc. Newton, Mass. 11/15 $3.30 Novelos completed a first round of private equity financing totaling $3.3M; Masthead Venture Partners was the lead institutional investor in this financing.
Noxxon Pharma AG Berlin 11/15 EUR20 (US$17) Noxxon raised over EUR20M in a second-round private equity financing; Merlin Biosciences led the financing, which included investors Westdeutsche Landesbank Girozentrale and Hannover Finanz GmbH
Onyvax Ltd. London 11/16 EUR17.5 (US$14.9) Onyvax raised US$14.9M through a private placement with MB Venture Capital Fund I, Merlin Biosciences Fund, 3i, S.R. One Ltd. and Alta Berkeley Venture Partners
Rademacher Group Ltd. Oxford, UK 11/20 8.6 (US$12.26) Rademacher raised US$12.26M in a funding round led by Johnson & Johnson Development Corp.; other investors were Northern Ventures, Apax and Advent Venture Partners
Scynexis Chemistry & Automation Inc. Research Triangle Park, N.C. 11/8 $15 The new company created by the spin-off of an Aventis CropScience research team received $15M in funding from a syndicate of venture capitalists and banks
Vela Pharmaceuticals Inc. Princeton, N.J. 11/1 $16.30 Vela raised $16.3M in a private equity financing led by New Enterprise Associates and Venrock Associates, and including Johnston Associates Inc. and MBF Capital Corp.
ViaCell Inc. Boston 11/15 $48 ViaCell raised $48M in mezzanine financing; investors included Deutsche Bank, Nomura International, the Stephens Group, Sofinov Societe Financiere D Innovation Inc., United Offshore Bank Venture Technology Investments Ltd. and Singapore s economic development board, as well as MPM Capital, Zero Stage Capital, Tullis Dickerson and Aurora Assets LLP
Wilex Biotechnology GmbH Munich, Germany 11/13 EUR30 (US$25.86) Wilex closed its third round of financing, raising US$25.86M; investors included Apax Partners and Co., Earlybird Venture Capital, TVM Techno Venture Management GmbH; Merlin BioSciences Ltd., Julius Baer Kapitalanlage AG, Bank Vontobel and BioConnect
DECEMBER
4SC AG Martinsried, Germany 12/12 EUR17.1 (US$14.9) Financing was led by 3i; other investors were Deutsche Venture Capital, BioM AG, Bayern Kapital, tbg, Beteiligungsgesellschaft der Deutschen Wirtschaft mbH and Mulligan Beteiligungs GmbH
Adprotech Ltd. Royston, UK 12/13 13 (US$18.9) Adprotech raised US$18.9M in its third-round financing; investors included 3i, Alice Ventures, Prelude Trust and Alta Berkeley Associates
Amphioxus Cell Technologies Inc. Houston 12/7 ND Amphioxus completed a private placement of preferred stock; Eaglestone Investment Partners I LP was lead investor
Anadys Pharmaceuticals Inc. San Diego 12/11 $21.20 Anadys raised $21.2M in a private financing, led by SG Capital Partners LLC; other investors included Advent International Corp., Atlas Ventures, International BM Biomedicine Holdings AG, Lombard Odier & Cie, Pacific Rim Ventures Co. Ltd., Sofinov and Venrock Associates
Biolex Inc. Pittsboro, N.C. 12/5 $6.50 Company completed its third round of venture financing; investors were Franklin Street Capital Intersouth Partners, Kitty Hawk Capital, the Wakefield Group and Tall Oaks Capital
BioMicro Systems Inc. Salt Lake City 12/22 $3 BioMicro completed an initial private placement totaling $3M
Caprion Pharmaceuticals Inc. Montreal 12/5 C$52.5 (US$40) Company raised US$40M in a private placement; Yorkton Securities Co. managed the placement and lead investors included Ventures West and Fidelity Management and Research Co.
Cardion AG Erkrath, Germany 12/18 EUR42.4 (US$35) Cardion completed a third-round financing led by TVM Techno Venture Management and including Deutsche Venture Capital and Alpinvest International BV, as well as BdW Beteiligungsgesellschaft der Deutschen Wirtschaft mbH (Dresdner Bank Group), CBG Commerz Beteiligungesellschaft mbH, NMT New Medical Technologies AG and Sal. Oppenheim Jr. & Cie
Circe Biomedical Inc. Lexington, Mass. 12/18 $28 Circe received $28M in private equity funding; investors included Asahi Chemical, Burrill & Co., HLM Management, Advanced Technology Ventures, SenMed Medical Ventures, Polaris Venture Partners, BancBoston Ventures, Bessemer Venture Partners, Spray Venture Partners, and Mayo Medical Ventures
Direct Therapeutics Inc. Redwood City, Calif. 12/13 $6 Direct Therapeutics raised $6M in a private placement led by VantagePoint Venture Partners; investor Loeb Partners Corp. also participated
Direvo Biotech AG Cologne, Germany 12/18 EUR8.75 (US$7.83) Direvo Biotech closed its first round of equity financing led by TVM Techno Venture Management
EirX Therapeutics Ltd. Dublin, Ireland 12/27 EUR3.6 (US$3.3) EirX raised US$3.3M in its second round of financing led by World Life Sciences plc; investors also included 3i plc and Enterprise Ireland
EntoMed SA Strasbourg, France 12/12 EUR20 (US$17.5) Lead investor is Apax Partners; other investors include Sofinov, Auriga Ventures, CDC Innovation, Oxford BioScience Partners and Atlas Ventures
Immunobiology Ltd. Cambridge, UK 12/13 0.6 (US$0.874) Immunobiology raised US$874,000 in seed funding
Ischemia Technologies Inc. Denver 12/21 $10.20 Ischemia completed its Series B financing with an aggregate investment of $10.2M; White Pines Ventures and members of Tenex Medical participated in the financing
MetaPhore Pharmaceuticals Inc. St. Louis 12/28 $13 MetaPhore completed a $13M Series B financing in a placement of preferred stock; included in round, led by Stifel Nicolaus CAPCO Fund, are Clayton Capital, Gryphon Holdings and Belleau Development
Molecular Staging Inc. New Haven, Conn. 12/19 $41.25 Molecular Staging completed a Series D preferred stock financing; investors included Investor AB, OrbiMed, CIBC Capital Partners and Cooper Hill Partners, as well as Domain Partners III, CHL Medical Partners and 3i Bioscience Investment Trust
Neuro 3D Mulhouse, France 12/27 EUR7.6 (US$6.7) Neuro 3D raised US$6.7M in seed funding from Sofinnova Partners and Apax Partners
Oncosis Inc. San Diego 12/19 $2.60 Oncosis received $2.6M in private financing from Iceland Genomic Ventures and existing investors
Oxagen Ltd. Abingdon, UK 12/21 30 (US$44) Oxagen raised US$44M in a private financing round led by Schroder Ventures and Abingworth Management; investors included funds managed by 3i Bioscience Investment Trust plc, BankInvest Biomedical Venture, CSFB Private Equity, Invesco Europe Ltd., Oppenheimer Funds, Pacific Rim Ventures Co. Ltd., the Palladin Group LP and Quest for Growth
PanTherix Ltd. Glasgow, Scotland 12/20 10.25 (US$15.1) PanTherix raised US$15.1M in a second-round funding led by MB Venture Capital and Scottish Equity Partners; the Merlin Biosciences Fund and the Merlin Fund invested 3.4M (US$5M)
Signase Inc. Houston 12/12 ND Signase closed an initial investment of an undisclosed amount; investors included A.M. Pappas & Associates, BioCapital Investment LP, as well as members of the management team
Tibotec Group NV Mechelen, Belgium 12/07 EUR41.5 (US$36.6) Tibotec raised US$36.6M in its third round of financing; investors included PharmaBioscience, Sofinim-Ackermans van Haaren, Fortis Group, KBC Banking & Insurance Group, IBEL NV, TrustCapital Partners NV and Manasales NV
Zyomyx Inc. Hayward, Calif. 12/4 $32.60 Zyomyx closed on its Series D financing raising over $32.6M; investors included Credit Suisse First Boston, Morgan Stanley Dean Witter, Softbank, Fujirebio, MDS Proteomics Inc., China Development Investment Bank, Sumitomo Corp. of America, Invus, NIF Ventures, Lombard Odier & Cie, Skyline Ventures, Alloy Ventures, eHealth Technology Fund, Yasuda Enterprise Development and 511 Equities Corp.
Notes:
ND = Not disclosed.